BindingDB logo
myBDB logout

63 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
26762835 342 Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).EBI Icahn School of Medicine at Mount Sinai
25000588 72 Discovery of selective and orally bioavailable protein kinase C┐ (PKC┐) inhibitors from a fragment hit.EBI AbbVie Bioresearch Center
23394126 170 Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).EBI Exelixis
23398373 88 Design and optimization of selective protein kinase C¿ (PKC¿) inhibitors for the treatment of autoimmune diseases.EBI Vertex Pharmaceuticals (Europe) Ltd.
23039927 44 Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases.EBI Martin-Luther University Halle-Wittenberg
22625994 28 Structure-activity studies on the spiroketal moiety of a simplified analogue of debromoaplysiatoxin with antiproliferative activity.EBI Kyoto University
9677190 49 Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.EBI University of California
18077363 314 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.EBI University of Oxford
17977729 40 Design and physicochemical properties of new fluorescent ligands of protein kinase C isozymes focused on CH/pi interaction.EBI Kyoto University
17935989 146 Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.EBI Abbott Laboratories
16876403 85 Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.EBI Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories
12672248 50 Kinase inhibitors: not just for kinases anymore.EBI Northwestern University
12954055 47 Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.EBI Johnson and Johnson Pharmaceutical Research and Development
12166950 208 Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.EBI Millennium Pharmaceuticals, Inc.
8289196 7 New hexahydroxybiphenyl derivatives as inhibitors of protein kinase C.EBI University of North Carolina
10999477 40 Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.EBI Kyoto University
 80 Synthesis and PKC inhibitory activities of balanol analogs with a cyclopentane substructureEBI TBA
22014550 337 Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).EBI Ansaris
21696964 12 Generation of 'Unnatural Natural Product' library and identification of a small molecule inhibitor of XIAP.EBI Keio University
21548579 4 Hippolides A-H, acyclic manoalide derivatives from the marine sponge Hippospongia lachne.EBI Second Military Medical University
21035334 55 Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors.EBI Martin Luther University Halle-Wittenberg
20817520 40 Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity.EBI Kyoto University
20346655 117 Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.EBI Abbott Laboratories
19926477 100 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.EBI Abbott Laboratories
 60 Synthesis and protein kinase C inhibitory activities of indane analogs of balanolEBI TBA
 64 Potent and selective PKC inhibitory 5-membered ring analogs of balanol with replacement of the carboxamide moietyEBI TBA
 84 Synthesis and biological evaluation of conformationally constrained bicyclic and tricyclic balanol analogues as inhibitors of protein kinase CEBI TBA
 40 Ring size effect in the PKC inhibitory activities of perhydroazepine analogs of balanolEBI TBA
 40 Heteroatom effect in the PKC inhibitory activities of perhydroazepine analogs of balanolEBI TBA
 85 Novel PKC inhibitory analogs of balanol with replacement of the ester functionalityEBI TBA
19379015 40 Conformationally constrained analogues of diacylglycerol (DAG). 31. Modulation of the biological properties of diacylgycerol lactones (DAG-lactones) containing rigid-rod acyl groups separated from the core lactone by spacer units of different lengths.EBI National Cancer Institute-Frederick
19109017 4 (-)-Cercosporamide derivatives as novel antihyperglycemic agents.EBI Daiichi Sankyo Co., Ltd
17875639 12 Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.EBI University of California-San Francisco
18072722 42 Synthesis, conformational analysis, and biological evaluation of 1-hexylindolactam-V10 as a selective activator for novel protein kinase C isozymes.EBI Kyoto University
17658776 109 Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.EBI Abbott Laboratories
17287122 79 Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors.EBI Abbott Laboratories
16682193 62 Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16640328 13 Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta.EBI Kyoto University
16216497 67 Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.EBI Abbott Bioresearch Center
15771419 134 Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.EBI Johnson & Johnson Pharmaceutical Research & Development
15317463 16 Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15149684 59 3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3.EBI Johnson & Johnson Pharmaceutical Research & Development
14552791 26 Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.EBI Lilly Spain S.A.
12954072 46 New bivalent PKC ligands linked by a carbon spacer: enhancement in binding affinity.EBI Georgetown University Medical Center
12941331 90 Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.EBI Johnson & Johnson Pharmaceutical Research & Development
12941324 66 Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.EBI Kyoto University
12749884 104 Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.EBI Lilly Research Laboratories
12672234 64 Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.EBI Boehringer Ingelheim Pharmaceuticals
11909733 30 Beta-carbolines as specific inhibitors of cyclin-dependent kinases.EBI Institute of Molecular and Cell Biology
11327599 25 Rational design, synthesis, and biological evaluation of rigid pyrrolidone analogues as potential inhibitors of prostate cancer cell growth.EBI Georgetotwn University
11266178 39 The amide hydrogen of (-)-indolactam-V and benzolactam-V8's plays a critical role in protein kinase C binding and tumor-promoting activities.EBI Kyoto University
11266177 26 The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.EBI Kyoto University
10397502 36 Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes.EBI Stanford University
9135029 29 Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivity.EBI Georgetown University Medical Center
9003521 249 Synthesis and protein kinase C inhibitory activities of balanol analogs with replacement of the perhydroazepine moiety.EBI A Division of Eli Lilly & Company
8709095 87 (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.EBI Lilly Research Laboratories
11451670 11 Hexosaminidase inhibitors as new drug candidates for the therapy of osteoarthritis.BDB The Scripps Research Institute
15689148 19 Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors.BDB Shanghai Institute of Materia Medica
15664516 21 Specificity and affinity of natural product cyclopentapeptide inhibitors against A. fumigatus, human, and bacterial chitinases.BDB University of Dundee
15026054 55 Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum.BDB CNRS